ACIP votes down use of LAIV for 2016-2017 flu season | CDC Online Newsroom | CDC
Media Statement For Immediate Release: Wednesday, June 22, 2016 Contact: Media Relations, (404) 639-3286 CDC’s Advisory Committee on Immunization Practices (ACIP) today voted that live attenuated influenza vaccine (LAIV), also known as the “nasal spray” flu vaccine, should not be used during the 2016-2017 flu season. ACIP continues to recommend annual flu vaccination, with either the inactivated i
Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015–16 Influenza Season
Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015–16 Influenza Season Lisa A. Grohskopf, MD1; Leslie Z. Sokolow, MSc, MPH1,2; Sonja J. Olsen, PhD1; Joseph S. Bresee, MD1; Karen R. Broder, MD3; Ruth A. Karron, MD4 This report updates the 2014 recommendations of the Advisory Committee on Immunization Practices
リリース、障害情報などのサービスのお知らせ
最新の人気エントリーの配信
j次のブックマーク
k前のブックマーク
lあとで読む
eコメント一覧を開く
oページを開く
COVID-19 Vaccination
Prevention and Control of Seasonal Influenza...
https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html
Coronavirus Disease 2019 (COVID-19)
Prevention and Control of Seasonal Influenza with Vaccines...
Chickenpox Prevention and Treatment
Interim Estimates of 2016–17 Seasonal Influenza Vaccine ...
Influenza Antiviral Medications: Clinician Summary
Rapid Influenza Diagnostic Tests | CDC
ACIP June 2016 Presentation Slides | Immunization Practices | CDC
Prevention and Control of Seasonal Influenza with Vaccines | MMWR
https://www.cdc.gov/features/salmonella-food/index.html
Guidance for School Administrators
Antiviral Agents for the Treatment and Chemoprophylaxis of Influenza
Infant Deaths Associated with Cough and Cold Medications --- Two States, 2005
CDC Public Health Grand Rounds
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine for Adults with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Children Aged 6–18 Years with Immunocompromising Conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP)